“…SPR sensing has been significantly developed in recent years to quantify biomarkers in complex matrixes, such as serum (Choi et al, 2010;Su et al, 2008 andLadd et al, 2009), plasma (Teramura et al, 2007), saliva (Yang et al, 2005) and cell lysate (Kyo et al, 2005). SPR biosensors have been shown to be suited for the detection of several cancer biomarkers (Sankiewicz et al, 2015) in solubilized samples, such as oropharyngeal squamous cell carcinoma (Liu et al, 2012), prostate cancer (Choi et al, 2010), colorectal, gastric, and pancreatic cancer (Su et al, 2008), intestinal cancer (Ladd et al, 2009), liver cancer (Teramura et al, 2007) and ovarian cancer (Liu et al, 2012) among others. However, serum and cell lysate screening on SPRi provide real time detection results in less time with low human error, but due to their protein and lipid rich matrix respectively, they expected to significantly foul on sensor surface.…”